SCHEMBL12401837

SCHEMBL12401837

Cc1cc(C(C)(C)C)c(C)cc1CO

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP2C9 P11712 6/20 0.41
CYP2C19 P33261 6/20 0.41
HIF1A Q16665 5/20 0.41
CYP2D6 P10635 2/20 0.41
HSD17B10 Q99714 1/20 0.41
SHBG P04278 1/20 0.39
HSPA5 P11021 2/20 0.38
CYP1A2 P05177 3/20 0.38
SMN1; SMN2 Q16637 5/20 0.37
ALDH1A1 P00352 5/20 0.37
CA2 P00918 2/20 0.37
POLB P06746 1/20 0.37
TYR P14679 1/20 0.37
ALOX15 P16050 4/20 0.36
KDM4E B2RXH2 1/20 0.36
MAPT P10636 1/20 0.36
ATP2A2 P16615 1/20 0.36
ATP2A3 Q93084 1/20 0.36
TP53 P04637 4/20 0.34
CYP3A4 P08684 2/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26853007 0.84 HSPA5 (0.39) CYP2C9CYP2C19HIF1ACYP2D6HSD17B10
SCHEMBL12401839 0.82 CYP2C9 (0.43) CYP2C9CYP2C19HIF1ACYP2D6HSD17B10
SCHEMBL5097086 0.81 SHBG (0.52) HIF1AHSD17B10SHBGCYP1A2ALDH1A1
SCHEMBL4066413 0.79 ALOX15 (0.54) CYP2C9CYP2C19HIF1ACYP2D6HSD17B10
SCHEMBL18561590 0.79 HTR2A (0.47) CA2ALOX15MAPTTP53CYP3A4
SCHEMBL12401835 0.79 HTR2A (0.51) CYP2C9CYP2C19HIF1ACYP2D6HSD17B10
SCHEMBL21500716 0.78 CYP2C9 (0.46) CYP2C9CYP2C19HIF1ACYP2D6HSD17B10
SCHEMBL7637748 0.78 CYP2C9 (0.38) CYP2C9CYP2C19HIF1ACYP2D6HSD17B10
SCHEMBL31522230 0.77 CYP2C9 (0.43) CYP2C9CYP2C19HIF1ACYP2D6HSD17B10
SCHEMBL394846 0.76 SHBG (0.48) HIF1AHSD17B10SHBGCYP1A2ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8372873-B2 Inhibitors of serine proteases VERTEX PHARMACEUTICALS INCORPORATED (US) 2013-02-12 US disclosed
US-20110182856-A1 INHIBITORS OF SERINE PROTEASES VERTEX PHARMACEUTICALS INCORPORATED (US) 2011-07-28 US disclosed
US-7964624-B1 Inhibitors of serine proteases VERTEX PHARMACEUTICALS INCORPORATED (US) 2011-06-21 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110182856-A1 INHIBITORS OF SERINE PROTEASES PRSS1, SPINT2, PRSS2 CYP2C9 1014/4885CYP2C19 1096/4885HIF1A 3923/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.